X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/neurosenses-paradigm-als-clinical-trial-demonstrates-up-to-73-improved-complication-free-survival-following-statistically-significant-slowing-of-disease-progression-302191862.html
https://www.prnewswire.com/news-releases/neurosense-demonstrates-statistically-significant-efficacy-and-survival-benefits-in-people-living-with-als-the-promising-results-from-the-12-month-paradigm-study-highlight-primecs-potential-as-a-disease-modifying-drug-302186838.html
https://www.prnewswire.com/news-releases/neurosense-management-provides-corporate-update-and-first-quarter-2024-financial-results-302180268.html
https://www.prnewswire.com/news-releases/neurosense-receives-delisting-notice-from-nasdaq-and-intends-to-appeal-302179372.html
https://www.prnewswire.com/news-releases/neurosense-vice-president-of-rd-shiran-zimri-phd-to-participate-in-the-3rd-annual-als-drug-development-summit-302149983.html
https://www.prnewswire.com/news-releases/neurosense-partners-with-phasev-to-optimize-upcoming-als-phase-3-trial-using-advanced-causal-machine-learning-302144941.html
https://www.prnewswire.com/news-releases/neurosense-announces-new-positive-data-analysis-from-paradigm-clinical-trial-demonstrating-statistically-significant-slowing-of-disease-progression-in-high-risk-als-patients-302137999.html
https://www.prnewswire.com/news-releases/neurosense-announces-first-quarter-2024-business-update-302134572.html
https://www.prnewswire.com/news-releases/neurosense-and-genetika-initiate-precision-medicine-collaboration-beginning-with-ongoing-phase-2-clinical-trial-in-alzheimers-disease-302122778.html
https://www.prnewswire.com/news-releases/neurosense-to-present-paradigm-data-at-the-american-academy-of-neurology-annual-meeting-april-16-2024-302115365.html
Market Place
Share 
